PNC-27

PNC-27 is an experimental synthetic peptide designed for cancer treatment, created by combining a segment derived from the p53 protein’s HDM-2 (MDM2) binding region with a sequence that enables cell membrane penetration. It is being investigated for its ability to specifically target cancer cells expressing HDM-2 on their surface, leading to the rapid formation of pores in the cell membrane and subsequent destruction of tumor cells—while leaving healthy cells unharmed, based on preclinical findings. Rather than inducing apoptosis like many traditional cancer therapies, it is studied primarily for its capacity to cause direct membranolysis and necrotic cell death in cancer cells.

Ongoing research involving PNC-27 typically focuses on:
– Experimental cancer treatments and targeted tumor therapies
– Studies of the HDM-2 / p53 signaling pathway
– Preclinical models of pancreatic, breast, colon cancers, melanoma, and leukemia
– Mechanisms of cancer cell destruction through membrane pore formation